Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.190
-0.040 (-3.25%)
At close: Aug 8, 2025, 4:00 PM
1.200
+0.010 (0.84%)
After-hours: Aug 8, 2025, 4:22 PM EDT

Company Description

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.

Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.

The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer.

Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Marker Therapeutics, Inc.
Marker Therapeutics logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees5
CEOJuan Vera

Contact Details

Address:
2450 Holcombe Blvd, MS: BCM251
Houston, Texas 77021
United States
Phone713 400 6400
Websitemarkertherapeutics.com

Stock Details

Ticker SymbolMRKR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001094038
CUSIP Number57055L107
ISIN NumberUS57055L2060
Employer ID88-0277072
SIC Code2834

Key Executives

NamePosition
Dr. Juan F. Vera M.D.Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director
Elizabeth DonnellyDirector of Administration
Dr. Maria-Bernadette Madel Ph.D.Director of Corporate Operations and External Communications
Edmund CheungVice President of Human Resources
Patricia AllisonHead of Clinical Operations
Mary Newman Ph.D.Head of Regulatory Affairs
Dr. Robert Z. Florkiewicz Sr., Ph.D.Senior Director of Molecular Biology and Virology

Latest SEC Filings

DateTypeTitle
Aug 5, 2025424B7Filing
Jun 17, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report
May 20, 20258-KCurrent Report
May 15, 202510-QQuarterly Report
May 15, 2025SCHEDULE 13G/AFiling
Apr 24, 2025ARSFiling
Apr 24, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2025DEF 14AOther definitive proxy statements
Mar 31, 20258-KCurrent Report